NCT01106807

Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne

Exploratory Study to Evaluate the Efficacy and Safety of CD07223 1.5% Gel and 0.5% Gel in Subjects With Acne

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 73 (actual)
• Sponsor: Galderma R&D · Industry
• Sex: All
• Age: 18 Years – 35 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the efficacy of CD07223 1.5% Gel and 0.5% gel in reducing inflammatory, non-inflammatory, and total acne lesion counts after 6 weeks of twice daily applications. The study will also evaluate the safety of the study products using tolerance and adverse event data.

Conditions

• Acne

Interventions

Type	Name	Description
DRUG	Epiduo vehicle gel	500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks
DRUG	CD07223	500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks
DRUG	CD07223	500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks
DRUG	Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel	500 microliters Epiduo Gel on one of the half-face for the morning dose

Timeline

• Start date: 2010-04-01
• Primary completion: 2010-09-01
• Completion: 2010-09-01
• First posted: 2010-04-20
• Last updated: 2021-02-18

Locations

9 sites across 1 country: United States